Kanna is having a moment — sold as a mood lift, a social lubricant, a nootropic, increasingly as a vape — and almost none of the marketing mentions the thing that matters most about it. The standardized extract that carries essentially all of its human research works, in part, by inhibiting serotonin reuptake. That is the same pharmacological target an SSRI antidepressant hits. It is genuinely interesting biology and it is also the reason this is not a casual supplement to stack on top of whatever else you are taking.
What kanna is
Kanna is a succulent native to southern Africa, with a long history of traditional use as a masticatory and medicine by San and Khoikhoi people, and later by European colonial farmers as a psychotropic tincture.[1] Its active constituents are the mesembrine alkaloids — mesembrine, mesembrenone and relatives. One naming point causes real confusion in the literature: the plant has been known as Sceletium tortuosum and is now also published under Mesembryanthemum tortuosum, so a search under one name misses papers filed under the other.[4]
Almost everything below concerns a single standardized commercial extract, Zembrin, formulated to contain consistent levels of those alkaloids. That distinction is not pedantry. Raw plant material, unstandardized capsules and the extract used in trials are not interchangeable, and different chemotypes of the plant have measurably different alkaloid profiles.
The mechanism, and why it is the safety story
The pharmacology is unusually well characterized for a supplement. The standardized extract acts as a dual PDE4 inhibitor and serotonin (5-HT) reuptake inhibitor, and a randomized, placebo-controlled fMRI study found acute effects in the human amygdala and in its connection to the hypothalamus — the circuitry that handles threat and stress response.[1] That is a real, drug-like mechanism demonstrated in a real imaging trial, and it is what makes kanna scientifically interesting rather than another herbal mood claim.
It is also the caution. Serotonin reuptake inhibition is the mechanism of the SSRI class. Stacking a serotonergic supplement on top of a prescribed serotonergic drug — an SSRI, an SNRI, an MAOI, tramadol, triptans, or another serotonergic supplement — is the situation in which serotonin toxicity arises, and nothing about kanna being sold as a botanical changes the receptor pharmacology. We are not aware of a trial designed to test that combination, which is precisely the point: the interaction is predicted by the mechanism and has not been characterized in humans. If you take a serotonergic medication, this is a conversation with your prescriber, not a purchase decision.
What the human trials actually found
The anxiety evidence is the most-cited and the most over-read. A randomized trial in healthy volunteers tested a single 25 mg dose of the standardized extract against laboratory-induced stress across two studies. Study 1 found no treatment effect. Study 2 found subjective anxiety significantly lower in the extract group before stress induction, plus an interaction between treatment and time on heart rate. The authors’ own framing is the honest one: they present it as the “first tentative behavioral evidence” supporting anxiolytic properties.[2] A single acute dose, in healthy people, with one of two studies null, is a starting point rather than a result.
On cognition, the often-quoted study is explicitly a proof-of-concept randomized controlled study in cognitively healthy subjects, framed around the PDE4 target.[3] Its author list is worth reading alongside its conclusions: it includes the Medical and Scientific lead of HG&H Pharmaceuticals, which produces Zembrin, and a representative of its US distributor. The same manufacturer scientist is also an author on the amygdala imaging paper above. None of that makes either finding wrong, and industry involvement in botanical research is normal — but when a compound’s entire human evidence base runs through one product, and the product’s own scientists co-author the key papers, independent replication is the missing ingredient, not a nice-to-have.
A separate randomized trial looked at eight days of supplementation on mood, visual tracking and reaction time in recreationally trained men and women, extending the picture into a short repeated-dose setting.[5] It is still days, not months.
What a 2026 review concluded
The most useful summary available is a 2026 review in Planta Med that set out to critically assess the in vivo animal and clinical studies of the plant, Zembrin and the mesembrine alkaloids, examining study designs, formulations and dosages. Its title states the finding plainly: mixed evidence for antidepressant and anxiolytic effects.[4] That is the state of play. There is no long-term human trial, no trial in diagnosed anxiety or depressive disorder, and no outcome data of the kind that would justify the confidence of the marketing.
The honest bottom line
Kanna is one of the more pharmacologically credible botanicals covered on this site — a characterized dual mechanism, a real imaging trial, a standardized extract with consistent alkaloid content. It is also one of the few where the mechanism itself argues for caution rather than reassurance. Treat it as a serotonergic agent that happens to be sold without a prescription: do not combine it with serotonergic medication, do not assume an unstandardized capsule matches the extract that was studied, and read the anxiety evidence as one tentative acute finding out of two studies rather than a settled effect. The gap between that and the way it is marketed is the same gap we find in ashwagandha and rhodiola — with the difference that neither of those works on the serotonin transporter.